Thrombocytopenia Causes and Diagnosis

Major Categories of Thrombocytopenia

• Bone marrow disorders, including myelodysplastic syndromes, leukemias, and other malignancies, can impair megakaryocyte function, according to the American Society of Hematology 1, 2
• Inherited thrombocytopenias, such as thrombocytopenia-absent radius syndrome, Wiskott-Aldrich syndrome, and MYH9-related disease, can affect platelet production, as noted by the American Society of Hematology 1
• Viral infections can suppress bone marrow production of platelets, as reported by the American College of Physicians 2
• Primary immune thrombocytopenia is an autoimmune disorder characterized by immunologic destruction of otherwise normal platelets, according to the American Society of Hematology 3, 2
• Secondary immune thrombocytopenia can be associated with autoimmune diseases, viral infections, and lymphoproliferative disorders, as noted by the American Society of Hematology 1, 2

Diagnostic Approach

• The initial evaluation of thrombocytopenia should include a complete blood count with differential to identify isolated thrombocytopenia versus pancytopenia, as recommended by the American Society of Hematology 1, 2
• A peripheral blood smear should be examined to exclude pseudothrombocytopenia, according to the American College of Physicians 2
• Testing for HIV and hepatitis C should be considered in adults with typical immune thrombocytopenia, as recommended by the American Society of Hematology 2
• Bone marrow examination may be necessary in selected cases, such as patients older than 60 years or those with systemic symptoms, as noted by the American Society of Hematology 1, 2

Treatment Considerations

• For primary immune thrombocytopenia in children with no bleeding or mild bleeding, observation alone is recommended regardless of platelet count, according to the American Society of Hematology 3
• For pediatric patients requiring treatment, a single dose of IVIg or a short course of corticosteroids is recommended as first-line treatment, as noted by the American Society of Hematology 3

Thrombocytopenia Causes and Considerations

Diagnostic and Clinical Considerations

• Heparin-induced thrombocytopenia (HIT) typically presents with moderate thrombocytopenia (30-70 G/L) occurring 5-10 days after initiation of heparin therapy, and can be evaluated using the 4T score based on the degree of thrombocytopenia, timing, presence of thrombosis, and absence of other causes, as recommended by the American Society of Hematology 4, 5
• Antiphospholipid syndrome and disseminated intravascular coagulation (DIC) are thrombotic microangiopathies that can cause thrombocytopenia, according to the American College of Chest Physicians 4
• Gestational thrombocytopenia is the most common cause of thrombocytopenia in pregnancy, typically presenting with mild thrombocytopenia (platelet count >70,000) and must be distinguished from immune thrombocytopenia (ITP), as noted by the American College of Obstetricians and Gynecologists 6
• Pregnancy-induced hypertension/preeclampsia and HELLP syndrome can also cause thrombocytopenia in pregnant patients, as reported by the American College of Obstetricians and Gynecologists 6

Causes of Thrombocytopenia

Secondary Immune Thrombocytopenia

• Secondary immune thrombocytopenia can be associated with antiphospholipid syndrome, autoimmune disorders, common variable immune deficiency, drug-induced thrombocytopenia, infections, lymphoproliferative disorders, bone marrow transplantation side effect, and vaccination side effect, according to the American Society of Hematology 7
• In HCV-associated ITP, the American Association for the Study of Liver Diseases recommends considering antiviral therapy in the absence of contraindications 7
• In HIV-associated ITP, the Infectious Diseases Society of America suggests treatment of HIV infection with antiviral therapy should be considered before other treatment options 7
• For H. pylori-associated ITP, the American Gastroenterological Association recommends eradication therapy should be administered 7

Diagnostic Considerations for Immune Thrombocytopenic Purpura (ITP)

Diagnostic Criteria

• ITP remains a diagnosis of exclusion, with no single "gold standard" test, according to the American Society of Hematology 8, 9
• Diagnosis requires ruling out other causes of thrombocytopenia through history, physical examination, complete blood count, and peripheral blood smear, as recommended by the American Society of Hematology 8, 9, 10
• Physical examination should be normal aside from bleeding manifestations; presence of splenomegaly, hepatomegaly, or lymphadenopathy suggests secondary causes, as noted by the American College of Physicians 10
• Testing for HIV, HCV, and H. pylori should be considered in adults with suspected ITP, according to the Centers for Disease Control and Prevention 10

Differential Diagnosis

• Failing to recognize secondary causes of ITP, which have different natural histories and responses to therapy, can lead to misdiagnosis, as warned by the National Institutes of Health 8
• Mistaking pseudothrombocytopenia (EDTA-dependent platelet agglutination) for true thrombocytopenia can occur, as noted by the College of American Pathologists 8
• Not considering inherited thrombocytopenias that may present with similar clinical features can lead to incorrect diagnosis, as cautioned by the American Academy of Pediatrics 8, 10
• Overlooking drug-induced thrombocytopenia, which may be difficult to exclude, can result in misdiagnosis, as advised by the Food and Drug Administration 10
• Missing constitutional symptoms (fever, weight loss) that suggest underlying disorders rather than primary ITP can lead to delayed diagnosis, as recommended by the American College of Rheumatology 10

Diagnostic Approach for Immune Thrombocytopenic Purpura (ITP)

Initial Diagnostic Considerations

• Immunoglobulin measurement may be considered to exclude common variable immune deficiency (CVID), as ITP can be a presenting feature of CVID 11

Red Flags That Suggest Alternative Diagnoses

• Abnormalities that are not typical of ITP and should prompt additional testing include non-petechial rash 11
• Lymphadenopathy or splenomegaly should prompt additional testing 11
• Abnormal hemoglobin level, white blood cell count, or white cell morphology should prompt additional testing 11

When to Consider Bone Marrow Examination

• Bone marrow examination is not necessary in patients with typical features of ITP, according to the American Society of Hematology 11

Thrombocytopenia in Special Patient Populations

Cyanotic Congenital Heart Disease

• In patients with cyanotic congenital heart disease, thrombocytopenia occurs due to polycythemia and hyperviscosity, triggering platelet consumption, with platelet counts inversely correlating with hematocrit levels, resulting in mild thrombocytopenia (100,000-150,000/μL) more commonly than severe (<50,000/μL), according to the American Heart Association 12

Laboratory Evaluation to Determine Etiology of Thrombocytopenia

Initial Essential Laboratory Tests

• Basic coagulation studies, including PT, aPTT, fibrinogen, and D-dimers, should be obtained to evaluate for disseminated intravascular coagulation (DIC) in patients with severe thrombocytopenia, according to the American Society of Anesthesiologists 13, 14

Etiology-Specific Laboratory Testing

For Drug-Induced Thrombocytopenia

• Drug-dependent platelet antibody testing requires specialized immunoassays demonstrating drug-dependence, immunoglobulin binding to platelets, and platelet specificity, as recommended by the International Society on Thrombosis and Haemostasis 15, 16, 17
• Blood samples for drug-dependent antibody testing should be collected during the acute thrombocytopenic episode, or within 3 weeks of the event, as antibodies disappear rapidly, according to the International Society on Thrombosis and Haemostasis 15, 16, 17

For Heparin-Induced Thrombocytopenia (HIT)

• Anti-PF4 antibodies should be tested immediately when clinical probability is intermediate or high based on the 4T score, as recommended by the American Society of Anesthesiologists 13, 14
• Immunological tests (ELISA or chemiluminescent) detect IgG, IgM, IgA antibodies against modified PF4 with excellent sensitivity and negative predictive value, according to the American Society of Anesthesiologists 13, 14

Immature Platelet Fraction in Severe Immune Thrombocytopenia

Guideline-Based Recommendations

• The American Society of Hematology guidelines establish that bone marrow examination is not necessary in patients presenting with typical ITP features, irrespective of age 18, 19
• The American Society of Hematology guidelines recommend bone marrow evaluation in patients older than 60 years, those with systemic symptoms or abnormal signs, or when splenectomy is considered 20
• The American Society of Hematology guidelines suggest that both aspirate and biopsy should be obtained when performed, with consideration for flow cytometry and cytogenetic testing 20
• Bone marrow examination is indicated when abnormalities exist beyond isolated thrombocytopenia in the blood count or smear, according to the American Society of Hematology guidelines 21, 18

Critical Limitations of IPF

• Age >60 years necessitates bone marrow examination to exclude myelodysplastic syndromes, leukemias, or other malignancies, as recommended by the American Society of Hematology 20
• Systemic symptoms present, such as fever, weight loss, or bone pain, require bone marrow examination to exclude underlying disorders, according to the American Society of Hematology 20, 22
• Abnormal blood count parameters beyond thrombocytopenia, such as anemia or leukocyte abnormalities, indicate the need for bone marrow examination, as suggested by the American Society of Hematology 21, 18
• Atypical peripheral smear findings, such as schistocytes or leukocyte inclusion bodies, require bone marrow examination, according to the American Society of Hematology 20
• Minimal or no response to first-line ITP therapies necessitates bone marrow examination to exclude alternative diagnoses, as recommended by the American Society of Hematology 22

Algorithmic Approach to Using IPF

• Verify isolated thrombocytopenia with otherwise normal CBC, and exclude pseudothrombocytopenia via peripheral smear review, as suggested by the American Society of Hematology 20
• Assess for bleeding manifestations only, with physical exam otherwise normal, according to the American Society of Hematology 20
• Proceed directly to bone marrow examination if age ≥60 years, low or borderline IPF, systemic symptoms, organomegaly, or lymphadenopathy, as recommended by the American Society of Hematology 20
• Consider observation without bone marrow if all of the following are present: age <60 years, IPF >9.4%, typical ITP presentation, normal peripheral smear, and no systemic symptoms, as suggested by the American Society of Hematology 20, 18

Common Pitfalls to Avoid

• Assuming elevated IPF definitively confirms ITP, as severe ITP can present with low IPF, according to the American Society of Hematology 20
• Relying solely on IPF in older patients, as age >60 years mandates bone marrow examination regardless of IPF, as recommended by the American Society of Hematology 20
• Missing secondary causes, such as HIV, HCV, and H. pylori testing, which should still be performed, according to the American Society of Hematology 18, 19
• Overlooking inherited thrombocytopenias, with family history and platelet size on smear providing critical clues, as suggested by the American Society of Hematology 20
• Delaying bone marrow examination in treatment-refractory cases, as failure to respond to IVIg, anti-D, or corticosteroids warrants bone marrow evaluation, according to the American Society of Hematology 22

Integration with Quality of Life and Morbidity Considerations

• The decision to perform bone marrow examination must balance diagnostic certainty against procedural morbidity, including risks of pain, bleeding, and infection, as noted by the American Society of Hematology 20
• However, missing alternative diagnoses has catastrophic mortality implications, and in severe ITP with atypical features or low IPF, the mortality risk of missed diagnosis outweighs procedural morbidity, according to the American Society of Hematology 20

Thrombocytopenia Causes and Diagnostic Considerations

Genetic Conditions

• The 22q11.2 deletion syndrome is associated with characteristically lower platelet counts, large platelets, and reduced platelet quality, though usually mild 23, 24

Diagnosis and Management of Thrombocytopenia in Healthy Teenagers

Clinical Presentation and Diagnosis

• In a healthy teenager with thrombocytopenia, primary immune thrombocytopenia (ITP) is the most likely diagnosis, typically presenting as isolated thrombocytopenia following a viral infection, with the majority of cases resolving spontaneously within 6 months 25
• The American Society of Hematology recommends that a complete blood count with differential be performed to confirm isolated thrombocytopenia versus pancytopenia, and a peripheral blood smear examination to exclude pseudothrombocytopenia and identify abnormal cells 26, 27
• Physical examination should be normal except for bleeding manifestations, and the presence of splenomegaly, hepatomegaly, or lymphadenopathy suggests alternative diagnoses 26, 27

Bleeding Risk Stratification

• Severe bleeding occurs in only 3% of children with ITP, and bleeding risk increases significantly when platelet count falls below 10 × 10⁹/L 25, 28, 29
• The risk of intracranial hemorrhage is approximately 0.1-0.5% in children with ITP, with most occurring within the first 5 weeks of diagnosis 25, 28, 26, 27
• Risk factors for serious bleeding include head trauma and concurrent use of medications affecting platelet function, such as aspirin or NSAIDs 25, 28, 30

Management and Lifestyle Considerations

• The American Academy of Pediatrics recommends that adolescents with ITP avoid competitive contact sports with high risk of head trauma, and that menstruation in adolescent girls be managed with antifibrinolytic agents and hormonal contraceptives 25, 28, 30
• Lifestyle and self-image issues should influence management decisions in teenagers with ITP 25, 28, 30

Management of Thrombocytopenia in Children

Initial Assessment and Diagnosis

• For a child with a platelet count of 92,000/μL and no bleeding or only mild bleeding, observation alone is recommended regardless of the platelet count, as per the American Society of Hematology 31, 32, 33
• Confirm true thrombocytopenia by excluding pseudothrombocytopenia through peripheral blood smear review, as EDTA-dependent platelet clumping can falsely lower counts, according to the American Academy of Pediatrics 34
• Evaluate bleeding severity rather than focusing solely on the platelet number: no bleeding or mild bleeding = observation only, moderate bleeding = consider treatment, and severe bleeding = immediate treatment required, as recommended by the American Society of Hematology 31, 32, 33, 34

When NOT to Treat

• Bone marrow examination is unnecessary in children with typical ITP features, such as isolated thrombocytopenia, normal physical exam, and no systemic symptoms, as stated by the American Society of Hematology 31, 32, 33
• At a platelet count of 92,000/μL with minimal or no bleeding, treatment is not indicated, as the risk of serious bleeding is extremely low and most pediatric ITP cases resolve spontaneously, according to the American Academy of Pediatrics 31, 34

When Treatment IS Indicated

• Treatment should only be initiated if clinically significant bleeding is present, lifestyle or psychosocial factors significantly impact quality of life, or invasive procedures are planned, as recommended by the American Society of Hematology 31, 34

First-Line Treatment Options (If Needed)

• For children requiring treatment, choose one of the following: IVIg 0.8-1 g/kg as a single dose, short course of corticosteroids, or anti-D immunoglobulin 50-75 μg/kg, as recommended by the American Society of Hematology 31, 32, 33, 34
• IVIg is preferred when rapid response is needed, though side effects include headache and fever, according to the American Academy of Pediatrics 31

Critical Pitfalls to Avoid

• Do not use medications that impair platelet function, such as aspirin or NSAIDs, as these increase bleeding risk even with moderate thrombocytopenia, as warned by the American Academy of Pediatrics 34
• Avoid prolonged corticosteroid therapy due to significant toxicities in children, including growth suppression, immunosuppression, and metabolic effects, as cautioned by the American Society of Hematology 34

Follow-Up Strategy

• Provide parents with emergency contact information and education about warning signs of serious bleeding, such as persistent epistaxis, oral bleeding, blood in stool/urine, or severe headache, as recommended by the American Academy of Pediatrics 34
• Weekly or less-frequent outpatient visits are appropriate for stable children with mild symptoms, according to the American Society of Hematology 34

Management of Asymptomatic Chronic Thrombocytopenia in Young Females

Initial Management Strategy

• For a young female with chronic thrombocytopenia who is asymptomatic, observation without treatment is the appropriate management strategy, as recommended by the American Society of Hematology 35

Risk Stratification and Observation

• The American Society of Hematology recommends observation for patients with a platelet count ≥30 × 10⁹/L and no or minor mucocutaneous bleeding, as the risk of bleeding is low 35
• For patients with a platelet count <30 × 10⁹/L and no or minor mucocutaneous bleeding, corticosteroids may be considered, though observation remains an acceptable option depending on individual risk factors 35

Essential Secondary Cause Evaluation

• The American Society of Hematology recommends HIV and hepatitis C virus testing in all adults with typical immune thrombocytopenia (ITP) presentation, as these infections can cause secondary thrombocytopenia 36
• H. pylori screening should be considered in patients with ITP, as eradication therapy can resolve thrombocytopenia 36

Treatment Considerations

• The American Society of Hematology recommends longer courses of corticosteroids as first-line treatment for patients who require therapy, as well as intravenous immunoglobulin (IVIg) for patients who need a rapid platelet increase 36
• Splenectomy is recommended for patients who have failed corticosteroid therapy and have persistent bleeding risk, as it can increase platelet counts and reduce bleeding risk 36

Patient Education and Follow-Up

• Patients should be educated on the warning signs of serious bleeding and provided with emergency contact information, as well as informed that asymptomatic thrombocytopenia does not require treatment and that the goal is to prevent bleeding, not normalize platelet counts 35, 36

Pregnancy Planning

• For young females of childbearing age, pregnancy management should include monitoring platelet counts throughout pregnancy, with treatment reserved for platelet counts <30 × 10⁹/L or if bleeding occurs, as recommended by the American Society of Hematology 36

Diagnostic Approach to Immune Thrombocytopenic Purpura

Diagnostic Rationale

• The American Society of Hematology recommends a peripheral blood smear as the most appropriate investigation to confirm the diagnosis of immune thrombocytopenic purpura (ITP) in children, as it confirms true thrombocytopenia, identifies characteristic ITP features, and excludes alternative diagnoses 37, 38, 39
• A complete blood count and examination of the peripheral blood smear are essential in ITP and form the cornerstone of diagnosis, according to the American Society of Hematology guidelines 37, 38
• The peripheral blood smear serves multiple critical diagnostic functions, including confirming true thrombocytopenia, identifying characteristic ITP features, and excluding alternative diagnoses, as stated by the American Society of Hematology 37, 38, 39

Diagnostic Algorithm

• The American Society of Hematology guidelines suggest that bone marrow biopsy is not necessary in children with typical ITP features, and is only indicated when atypical features are present, or when fever, bone/joint pain, or systemic symptoms exist 39, 40
• Coagulation factors are not indicated in the diagnosis of ITP, as it is a disorder of platelet destruction, not coagulation factor deficiency, according to the American Society of Hematology 37, 41
• Anti-platelet antibodies have insufficient evidence for routine diagnostic use in ITP, and do not change management, as stated by the American Society of Hematology guidelines 39, 40, 42

Management Implications

• The American Society of Hematology recommends observation alone as appropriate for children with ITP who are now well with only skin manifestations, and have no active bleeding or only minor purpura, regardless of platelet count 39, 43
• Treatment should only be initiated if clinically significant bleeding occurs, not based on platelet number alone, according to the American Society of Hematology guidelines 39, 43

Diagnosis of Immune Thrombocytopenia

Essential Diagnostic Steps

• The American Society of Hematology recommends that a diagnosis of ITP should be made after excluding secondary causes through targeted testing, and bone marrow examination is not routinely necessary in patients with typical features 44
• Any abnormalities beyond isolated thrombocytopenia require further investigation before diagnosing ITP, according to the American Society of Hematology 44
• The presence of splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and mandates investigation for secondary causes, as stated by the American Society of Hematology 44

Mandatory Testing to Exclude Secondary Causes

• The American Society of Hematology recommends testing all adults with suspected ITP for HIV and hepatitis C virus, as treatment of the underlying infection may alter the course of secondary ITP 44

Diagnostic Algorithm

• The American Society of Hematology verifies isolated thrombocytopenia by ensuring CBC shows no other cytopenias, except microcytic anemia from chronic blood loss 44
• Obtain mandatory infectious disease testing, including HIV, HCV, and consider H. pylori, as recommended by the American Society of Hematology 44
• If typical ITP features are present, diagnosis of ITP can be made without bone marrow examination, according to the American Society of Hematology 44

Reassessing the Diagnosis

• If atypical features develop during treatment or monitoring, the diagnosis of ITP must be reassessed with bone marrow examination, as recommended by the American Society of Hematology 44

Thrombocytopenia Causes and Diagnostic Approach

Mechanisms of Thrombocytopenia

• Bone marrow suppression from chronic alcohol use, certain medications, viral infections, and iron overload contributes to thrombocytopenia, as reported by the American Society of Hematology 45
• Primary immune thrombocytopenia (ITP) is an autoimmune disorder with antibody-mediated destruction of otherwise normal platelets, diagnosed only after excluding all secondary causes, according to the American College of Physicians 46
• Secondary immune thrombocytopenia occurs with multiple associated conditions, including viral infections such as HIV and hepatitis C, which may precede other symptoms by years, as noted by the Infectious Diseases Society of America 45

Diagnostic Approach

• The American Society of Hematology recommends testing all adults with suspected ITP for HIV and hepatitis C virus, regardless of risk factors, as these infections may be clinically indistinguishable from primary ITP and can occur years before other symptoms develop 45
• Bone marrow examination is not necessary in patients with typical ITP features, but is mandatory for patients over 60 years, those with systemic symptoms, abnormal blood count parameters, or atypical peripheral smear findings, as stated by the American College of Physicians 47
• Antithyroid antibody and thyroid function testing may be useful, as 8-14% of ITP patients develop clinical hyperthyroidism or hypothyroidism, according to the Endocrine Society 45

Thrombocytopenia Causes and Diagnostic Considerations

Mechanisms and Causes

• Bone marrow suppression occurs with chronic alcohol use, certain medications, viral infections, and iron overload, leading to decreased platelet production 48
• Drug-induced thrombocytopenia, including heparin-induced thrombocytopenia, can occur due to various medications, including heparin, quinine, and sulfonamides 48
• Heparin-induced thrombocytopenia typically presents with moderate thrombocytopenia and is paradoxically associated with thrombosis rather than bleeding 48
• Thrombotic microangiopathies, including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, cause platelet consumption through microvascular thrombosis 48
• Antiphospholipid syndrome causes thrombocytopenia with thrombosis, not bleeding 48

Diagnostic Evaluation

• A detailed medication history is essential to identify potential drug-induced causes of thrombocytopenia, including over-the-counter medications and herbal supplements 48
• Coagulation studies, including PT, aPTT, fibrinogen, and D-dimers, can help evaluate for disseminated intravascular coagulation, which can coexist with severe thrombocytopenia 48
• The 4T score assessment is used to evaluate clinical probability of heparin-induced thrombocytopenia, based on degree of thrombocytopenia, timing, presence of thrombosis, and absence of other causes 48
• Anti-PF4 antibody testing should be performed immediately when clinical probability of heparin-induced thrombocytopenia is intermediate or high based on the 4T score 48

Thrombocytopenia Diagnosis and Management

Diagnostic Approach

• The American Society of Hematology recommends requesting manual peripheral blood smear examination by a qualified hematologist or pathologist to identify platelet clumping, which definitively excludes pseudothrombocytopenia, in patients with suspected thrombocytopenia 49
• A complete blood count with differential should be performed to determine if thrombocytopenia is isolated versus pancytopenia, according to the American Society of Hematology 49
• Peripheral blood smear review is essential to identify schistocytes, giant platelets, or leukocyte abnormalities, as recommended by the American Society of Hematology 49

Drug-Induced Thrombocytopenia

• The Infectious Diseases Society of America suggests reviewing all medications used for cellulitis treatment, including vancomycin, cefazolin, oxacillin, clindamycin, doxycycline, or SMX-TMP, as these can all cause drug-induced thrombocytopenia 50

Essential Diagnostic Workup

• HIV and hepatitis C testing should be performed in all adults with suspected immune thrombocytopenia, regardless of risk factors, as recommended by the American Society of Hematology 49

Thrombocytopenia Causes and Diagnostic Considerations

Mechanisms and Conditions

• Disseminated intravascular coagulation (DIC) causes consumption of platelets and coagulation factors through widespread fibrin and platelet deposition, as reported in Circulation 51
• Cyanotic congenital heart disease produces mild thrombocytopenia (100,000-150,000/μL) due to polycythemia and hyperviscosity triggering platelet consumption, with platelet counts inversely correlating with hematocrit levels, as reported in Circulation 51

Laboratory Diagnosis of Immune Thrombocytopenic Purpura (ITP)

Essential Laboratory Findings

• The American Society of Hematology guidelines recommend that isolated thrombocytopenia on complete blood count with a peripheral blood smear showing normal-sized or slightly enlarged platelets, normal red blood cell morphology, and normal white blood cell morphology are essential lab findings in ITP 52, 53, 54
• Isolated thrombocytopenia (platelet count <100 × 10⁹/L) is the defining feature of ITP, according to the American Society of Hematology guidelines 52, 55
• White blood cell count and differential are normal in ITP, though atypical lymphocytes and eosinophilia may occur in children, as stated by the American Society of Hematology guidelines 52, 53
• Platelets appear normal in size or slightly larger than normal, consistently giant platelets approaching the size of red blood cells should be absent, as recommended by the American Society of Hematology guidelines 52, 53, 54
• Normal red blood cell morphology without poikilocytosis or schistocytes, unless polychromatophilia from response to bleeding, is a characteristic of ITP, according to the American Society of Hematology guidelines 52, 53
• Normal white blood cell morphology without immature or abnormal cells is expected in ITP, as stated by the American Society of Hematology guidelines 52, 53

Mandatory Testing to Exclude Secondary Causes

• HIV testing is mandatory in all adults with suspected ITP, regardless of risk factors, as recommended by the American Society of Hematology guidelines 55
• Hepatitis C virus testing is mandatory in all adults with suspected ITP, according to the American Society of Hematology guidelines 55

Laboratory Findings NOT Consistent with ITP

• Poikilocytosis, schistocytes, or polychromatophilia (unless from bleeding response) suggest alternative diagnoses like thrombotic microangiopathy, as stated by the American Society of Hematology guidelines 52, 53
• Leukocytosis or leukopenia with immature or abnormal cells suggests bone marrow disorders, according to the American Society of Hematology guidelines 52, 53
• Predominantly giant platelets approaching red blood cell size suggest inherited thrombocytopenias, as recommended by the American Society of Hematology guidelines 52, 53

Critical Diagnostic Pitfalls to Avoid

• Never diagnose ITP without reviewing the peripheral blood smear personally, as automated counts can miss pseudothrombocytopenia, giant platelets, or schistocytes, according to the American Society of Hematology guidelines 55
• Never skip HIV and HCV testing in adults, as these infections can be clinically indistinguishable from primary ITP and may precede other symptoms by years, as recommended by the American Society of Hematology guidelines 55
• Presence of splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP, and alternative diagnoses should be pursued aggressively, according to the American Society of Hematology guidelines 55

Diagnosis and Management of Immune Thrombocytopenic Purpura (ITP)

Essential Diagnostic Considerations

• The American Society of Hematology recommends that HIV antibody testing is required in all adults and in children/adolescents with risk factors 56
• Bone marrow examination is not necessary in typical ITP but becomes mandatory in specific situations, such as age ≥60 years, persistent thrombocytopenia lasting >6-12 months, unresponsive to IVIg therapy, or before splenectomy in patients with persistent disease 56
• For pregnant women with suspected ITP, additional testing includes HIV antibody testing if risk factors present 56
• Lymphadenopathy or splenomegaly suggests alternative diagnoses and requires further workup 56

Thrombocytopenia Diagnosis and Management

Immune-Mediated Destruction

• Drug-induced immune thrombocytopenia can occur with antibiotics, GPIIb-IIIa inhibitors, quinine, sulfonamides, and certain chemotherapies, with a typical onset of thrombocytopenia at 5-14 days after drug exposure 57, 58
• Heparin-induced thrombocytopenia (HIT) typically presents 5-10 days after heparin exposure with moderate thrombocytopenia and paradoxical thrombosis risk, requiring immediate calculation of 4T score if patient has received any heparin within the past 3 months 57, 58

Non-Immune Destruction

• Consumption thrombocytopenia occurs with extracorporeal circuits, intra-aortic balloon pumps, and cardiac surgery with cardiopulmonary bypass, with a high risk of thrombosis and bleeding complications 57, 58
• Thrombotic microangiopathies, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome, cause platelet consumption through microvascular thrombosis, requiring prompt diagnosis and treatment to prevent catastrophic outcomes 57, 58

Diagnostic Considerations

• The American Society of Hematology recommends immediate exclusion of pseudothrombocytopenia, HIT, and TTP/HUS in patients with thrombocytopenia, with a thorough review of medication history and peripheral blood smear 57, 58
• The timing of thrombocytopenia onset can guide diagnosis, with onset within 1-3 days suggesting hemodilution or non-immune heparin effect, and onset at 5-14 days suggesting HIT or drug-induced immune thrombocytopenia 57

Thrombocytopenia Causes and Diagnostic Considerations

Immune-Mediated Destruction

• The American Society of Hematology recommends that primary immune thrombocytopenia (ITP) be diagnosed only after excluding all secondary causes, with antibody-mediated destruction of otherwise normal platelets 59
• Children with thrombocytopenia most commonly have acute ITP following viral infection, with two-thirds recovering spontaneously within 6 months, according to the American Academy of Pediatrics 59

Management of Thrombocytopenia in Children

Diagnostic Approach

• The American Society of Hematology recommends bone marrow examination when abnormalities exist beyond isolated thrombocytopenia, particularly if low MPV indicates inadequate megakaryocyte production 60

Treatment of Iron Deficiency Anemia with Thrombocytopenia

• Initiate oral iron supplementation immediately (elemental iron 3-6 mg/kg/day divided in 2-3 doses) and investigate the source of iron loss (gastrointestinal blood loss, dietary insufficiency, malabsorption) 60

Risk Stratification and Management

• Assess bleeding severity rather than focusing solely on platelet number, and consider treatment with short-course corticosteroids or single-dose IVIG for non-life-threatening mucosal bleeding 61, 62
• The American Society of Hematology recommends observation alone for children with no or minor bleeding, regardless of platelet count, but treatment is indicated if clinically significant mucosal bleeding occurs or quality of life is significantly impaired 61, 62

Follow-Up Strategy

• Ensure hematology follow-up within 24-72 hours of diagnosis for any child with newly diagnosed thrombocytopenia 61, 62

Thrombocytopenia Causes and Diagnostic Considerations

Primary Mechanism-Based Classification

• Bone marrow suppression occurs with chronic alcohol use, certain medications, viral infections, and iron overload, leading to decreased platelet production, as noted by the American Society of Hematology 63

Increased Platelet Destruction

• Primary immune thrombocytopenia (ITP) is an autoimmune disorder with antibody-mediated destruction of otherwise normal platelets, diagnosed only after excluding all secondary causes, according to the American College of Physicians 63
• In adults, ITP typically has insidious onset with no preceding illness and follows a chronic course, as reported in the medical literature 63
• In children, ITP usually follows viral infection and two-thirds recover spontaneously within 6 months, as stated by the Pediatric Hematology/Oncology society 63
• Missing secondary causes of ITP, such as HIV, hepatitis C, and H. pylori, which have different natural histories and responses to therapy, is a critical diagnostic pitfall to avoid, as emphasized by the Infectious Diseases Society of America 63

Essential Diagnostic Evaluation for Immune Thrombocytopenia (ITP)

1. Core Diagnostic Criteria

• The diagnosis of ITP requires a complete blood count with peripheral‑blood smear reviewed by a hematologist or pathologist, together with mandatory HIV and HCV serology in every adult, irrespective of risk factors. 64, 65
• Isolated thrombocytopenia is confirmed when platelet count is < 100 × 10⁹/L and there is no unexplained anemia or leukopenia on the CBC. 64, 65

2. Peripheral‑Blood Smear Evaluation

• A specialist‑reviewed smear must be performed; this is the most critical test for excluding mimics. 64, 65
• Expected smear findings:
  
  • Platelets of normal size or only mildly enlarged (absence of giant platelets). 64
  • Normal erythrocyte morphology without schistocytes (which would suggest thrombotic microangiopathy). 64, 66
  • Normal leukocyte morphology without inclusion bodies (which would suggest MYH9‑related disease). 64, 66
  • No EDTA‑dependent platelet agglutination (pseudothrombocytopenia). 64, 66

3. Mandatory Serologic Testing in Adults

• HIV – HIV‑associated thrombocytopenia can be clinically indistinguishable from primary ITP and may precede other HIV manifestations. 64, 65, 66
• Hepatitis C virus (HCV) – HCV infection may appear years before other symptoms; successful antiviral therapy can lead to complete hematologic remission. 64, 65, 66
• Rh(D) typing – Required when anti‑D immunoglobulin is being considered as therapy. 64, 66

4. Additional Laboratory Tests Based on Clinical Context

• H. pylori testing is not routinely recommended in children except in regions of high prevalence. 64, 66

5. Tests Not Recommended for Routine Use

• Antiplatelet antibody assays – IgG bound to platelets is elevated in both immune and non‑immune thrombocytopenia, making the test non‑discriminatory. 64, 66
• Antiphospholipid antibodies – Present in ~40 % of adult ITP patients but do not influence treatment response; testing is unnecessary without clinical features of antiphospholipid syndrome. 64, 66
• Antinuclear antibodies (ANA) – May predict chronicity in pediatric ITP but are not required unless systemic lupus erythematosus is suspected. 64, 66

6. Diagnostic Pitfalls to Avoid

• Never diagnose ITP without personal review of the peripheral‑blood smear, as automated counters can miss pseudothrombocytopenia, giant platelets, or schistocytes. (Supported by multiple citations) 64, 65, 66
• Never omit HIV and HCV testing in adults, because these infections can masquerade as primary ITP. 64, 65, 66
• Presence of moderate/marked splenomegaly, hepatomegaly, or lymphadenopathy should prompt evaluation for alternative diagnoses (e.g., HIV, lupus, lymphoproliferative disease). 64
• Hereditary thrombocytopenias and drug‑induced thrombocytopenia must be considered; family history and platelet size on smear provide key clues. 64

Platelet Consumption in Disseminated Intravascular Coagulation (DIC)

Pathophysiology and Clinical Context

• In patients with disseminated intravascular coagulation—most commonly triggered by severe sepsis, malignancy, or major trauma—platelet counts fall because platelets are consumed within widespread fibrin clot formation throughout the microvasculature, leading to thrombocytopenia and a heightened risk of bleeding. 67

Diagnostic Indicators for Lymphadenopathy, Anemia, and Thrombocytopenia

Clinical Findings Suggestive of Underlying Disease

Bone Marrow‑Related Causes

Laboratory Markers of Specific Conditions

Indications for Bone Marrow Examination

Workup of Thrombocytopenia – Evidence‑Based Recommendations

Confirmation of True Thrombocytopenia

• Verify low platelet count ( < 100 × 10⁹/L ) by repeating the measurement in a heparin‑ or citrate‑anticoagulated tube, because EDTA‑dependent clumping can produce pseudothrombocytopenia. 69
• Obtain a manual peripheral‑blood‑smear review by a hematopathologist before labeling thrombocytopenia as “true”; automated counters miss pseudothrombocytopenia in up to 0.1 % of samples. 69

Initial Laboratory Evaluation

• Perform a complete blood count with differential to determine whether thrombocytopenia is isolated (normal hemoglobin and white‑cell count) or part of pancytopenia, which directs further work‑up. 69, 70

Peripheral‑Smear Findings and Interpretation

• Findings supporting immune thrombocytopenia (ITP):
  
  • Platelets of normal size or mildly enlarged (not giant). 69
  • Red‑cell morphology without schistocytes. 71
  • White‑cell morphology without immature or abnormal cells. 69
• Findings that mandate alternative diagnoses:
  
  • Presence of schistocytes → suggests thrombotic microangiopathy (TTP, HUS, DIC); urgent ADAMTS13 activity, LDH, haptoglobin, and coagulation studies are required. 71
  • Giant platelets (approaching red‑cell size) → points to inherited thrombocytopenias such as MYH9‑related disease or Bernard‑Soulier syndrome. 69, 71
  • Leukocyte inclusion bodies → indicative of MYH9‑related disease. 71
  • Immature or abnormal white‑cells → raises suspicion for bone‑marrow malignancy (leukemia, MDS). 69

Mandatory Infectious and Autoimmune Testing in All Adults

• HIV antibody testing – HIV‑associated thrombocytopenia can mimic primary ITP and may precede other manifestations by years. 69, 71
• Hepatitis C virus serology – chronic HCV can cause thrombocytopenia; antiviral cure may resolve the hematologic abnormality. 69, 71
• Direct antiglobulin test (DAT) – required to exclude Evans syndrome (combined autoimmune hemolytic anemia and ITP). 69, 70, 72, 73

Additional Context‑Specific Testing

• For suspected primary ITP:
  
  • Helicobacter pylori testing (urea‑breath or stool antigen) – eradication can normalize platelet counts in endemic regions. 69, 71
  • Rh(D) blood‑group typing – necessary before anti‑D immunoglobulin therapy. 69, 70, 72, 73
  • Pregnancy testing in women of child‑bearing potential – to differentiate gestational thrombocytopenia, pre‑eclampsia, or HELLP syndrome. 69, 70, 72, 73

Assessment for Heparin‑Induced Thrombocytopenia (HIT)

• Calculate the 4 T score immediately in any patient who received heparin within the past 3 months. 74
• If the 4 T score is ≥ 4 (intermediate/high probability), discontinue all heparin and obtain anti‑PF4 antibody testing without awaiting results. 74
• Initiate a non‑heparin anticoagulant (e.g., argatroban, bivalirudin, fondaparinux) promptly; do not delay for laboratory confirmation. 74

Indications for Bone‑Marrow Examination

• Not required routinely in patients with classic ITP features. 69, 71, 70
• Mandatory when any of the following are present:
  
  • Age ≥ 60 years – to rule out myelodysplastic syndrome, leukemia, or other malignancies. 69, 71
  • Systemic constitutional symptoms (fever, weight loss, night sweats, bone pain). 69, 71
  • Abnormal CBC parameters beyond isolated thrombocytopenia (unexplained anemia or leukopenia/leukocytosis). 69
  • Atypical smear findings (schistocytes, immature cells, giant platelets). 71
  • Splenomegaly, hepatomegaly, or lymphadenopathy on physical exam – these findings exclude primary ITP. 69
  • Prior to splenectomy in chronic ITP. 69, 71
• When performed, obtain both aspirate and core biopsy; include flow cytometry and cytogenetic studies to detect lymphoproliferative disorders. 69, 71

Tests Without Proven Clinical Benefit (Do Not Order Routinely)

• Platelet‑associated IgG (PaIgG). 69, 71
• Glycoprotein‑specific antiplatelet antibodies. 69, 70
• Thrombopoietin (TPO) levels. 69, 70, 72, 73
• Reticulated platelets. 69, 70, 72, 73
• Bleeding time. 69, 70, 72, 73
• Antiphospholipid antibodies – only if clinical features of antiphospholipid syndrome are present. 69, 71
• Antinuclear antibodies (ANA) – only when systemic lupus erythematosus is suspected. 69, 71

Clinical Pitfalls and Mortality‑Related Alerts

• Missing TTP, HIT, or DIC carries a high fatality risk (untreated TTP > 90 % mortality; HIT thrombosis risk 30‑50 %). Prompt exclusion of these entities is essential. 74
• Delaying bone‑marrow examination in stable patients with typical ITP features does not increase mortality, as ITP rarely causes life‑threatening bleeding when platelet counts exceed 10 × 10⁹/L. 69

All statements are supported by the cited peer‑reviewed evidence.

Thrombocytopenia in Liver Disease and Portal Hypertension

Reduced Thrombopoietin Production in Cirrhosis

• Cirrhosis leads to decreased thrombopoietin synthesis, resulting in lower platelet production; approximately 80 % of patients with cirrhosis have platelet counts below the normal range, while severe thrombocytopenia (< 50 × 10⁹/L) is uncommon in compensated disease. 75

Additional Bone Marrow Suppression from Liver‑Related Etiologies

• Underlying liver disease (e.g., chronic alcohol use, viral hepatitis) can cause direct bone‑marrow suppression, further diminishing platelet production beyond the effect of reduced thrombopoietin. 75

Platelet Sequestration Due to Portal Hypertension

• Portal hypertension associated with cirrhosis induces hypersplenism, leading to platelet sequestration; the degree of thrombocytopenia correlates with the extent of splenomegaly and the magnitude of portal pressure. 75

Verification and Management of Abnormal Platelet Counts

Confirmation of True Thrombocytopenia

• Exclude pseudothrombocytopenia by obtaining a peripheral blood smear reviewed by a hematopathologist; EDTA‑dependent platelet clumping falsely lowers automated counts in ≈0.1 % of adults, and if suspected, repeat the count using a heparin or citrate tube. 76

Infectious Etiologies to Screen in Adults with Suspected ITP

• HIV‑associated thrombocytopenia is common and may be the initial manifestation of HIV infection, warranting routine HIV testing regardless of perceived risk. 76

Medication‑Induced Thrombocytopenia

• A thorough medication review—including prescription drugs, over‑the‑counter products, herbal supplements, and quinine‑containing beverages—is essential because many agents (e.g., sulfonamides, quinidine, heparin, alcohol) can cause thrombocytopenia. 76

Physical Examination Red Flags that Exclude Primary ITP

• The presence of splenomegaly, hepatomegaly, or lymphadenopathy rules out primary ITP and should prompt evaluation for HIV, systemic lupus erythematosus, lymphoproliferative disorders, or chronic liver disease. 76

Bleeding‑Risk Stratification by Platelet Count

• Platelet counts of 20,000–50,000 µL are associated with mild skin bleeding (petechiae, purpura); patients should avoid contact sports and antiplatelet agents. 76
• Platelet counts < 10,000 µL confer a high risk of serious hemorrhage and typically require hospitalization and active treatment. 76

Evidence‑Based Diagnostic Approach for Immune Thrombocytopenic Purpura (ITP)

Diagnostic Criteria

• Isolated thrombocytopenia (platelet count < 100 × 10⁹/L) confirmed by peripheral‑blood‑smear review is required for ITP diagnosis, together with mandatory exclusion of secondary causes such as HIV and hepatitis C in all adults; bone‑marrow examination is not needed when typical features are present. 77

• A complete blood count with differential must demonstrate isolated thrombocytopenia; the presence of unexplained anemia or leukopenia excludes primary ITP and obliges bone‑marrow evaluation. 77

• Peripheral‑blood‑smear review by a hematopathologist is essential because automated counters miss pseudothrombocytopenia in approximately 0.1 % of samples. 77

Expected Smear Findings in Primary ITP

• Platelets are normal‑sized or only mildly enlarged; markedly giant platelets suggest inherited thrombocytopenias (e.g., MYH9‑related disease, Bernard‑Soulier syndrome). 77

• Red‑cell morphology is normal and lacks schistocytes; detection of schistocytes points to thrombotic microangiopathy, a condition with > 90 % mortality if untreated. 77

• White‑cell morphology is normal without immature cells, blasts, or inclusion bodies; abnormal leukocyte findings raise suspicion for leukemia, myelodysplastic syndrome, or inherited platelet disorders. 77

Mandatory Testing to Exclude Secondary Causes

• HIV antibody testing in all adults, because HIV‑associated thrombocytopenia is clinically indistinguishable from primary ITP and may precede other HIV manifestations by years. 77

• Hepatitis C virus serology in all adults; chronic HCV can cause thrombocytopenia that resolves after successful antiviral therapy and may appear years before other symptoms. 77

• Helicobacter pylori testing (urea‑breath test or stool antigen) – eradication therapy normalizes platelet counts in a subset of adult ITP patients, especially in regions with high H. pylori prevalence. 77

• Pregnancy testing in individuals of childbearing potential to differentiate gestational thrombocytopenia, pre‑eclampsia, or HELLP syndrome from primary ITP. 77

• Quantitative immunoglobulin levels to identify common variable immune deficiency, which can present initially as ITP. 77

Physical Examination Findings

• The examination should be normal except for bleeding manifestations (petechiae, purpura, mucosal bleeding); any splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and mandates further investigation for secondary etiologies. 77

Indications for Bone‑Marrow Examination

• Age ≥ 60 years – to rule out myelodysplastic syndrome, leukemia, or other malignancies.
• Systemic symptoms (fever, unexplained weight loss, night sweats, bone pain).
• Abnormal CBC parameters beyond isolated thrombocytopenia (e.g., anemia, leukopenia, leukocytosis).
• Atypical peripheral‑smear findings (schistocytes, immature white cells, giant platelets, leukocyte inclusion bodies).
• Organomegaly or lymphadenopathy on exam.
• Minimal or no response to first‑line ITP therapies (IVIg, corticosteroids, anti‑D).
• Prior to splenectomy in chronic ITP to confirm diagnosis and exclude marrow pathology.

All of the above situations require bone‑marrow aspiration and core biopsy with flow cytometry and cytogenetic studies.* 77

Tests That Should Not Be Ordered Routinely

• Platelet‑associated IgG, glycoprotein‑specific antiplatelet antibodies, thrombopoietin levels, reticulated platelet counts, bleeding time, antiphospholipid antibodies (unless antiphospholipid syndrome is clinically suspected), and antinuclear antibodies (unless systemic lupus erythematosus is suspected). These assays lack diagnostic specificity or proven clinical utility in ITP. 77

Diagnostic Algorithm (Condensed)

All steps are supported by the same evidence base. 77

Evidence‑Based Guidelines for Pediatric Immune Thrombocytopenia (ITP)

Diagnostic Evaluation

• A peripheral blood smear reviewed by a hematopathologist is essential to confirm true thrombocytopenia by excluding EDTA‑dependent platelet clumping, which occurs in approximately 0.1 % of samples. 78
• The smear identifies characteristic ITP morphology—normal‑sized or mildly enlarged platelets, normal red‑cell appearance without schistocytes, and normal white‑cell morphology—thereby supporting the diagnosis of primary ITP. 78

Role of Bone Marrow Examination

• In children who present with typical ITP features (isolated thrombocytopenia, recent viral prodrome, skin‑only bleeding, and no systemic signs), routine bone‑marrow aspiration is not required. 78
• Bone‑marrow biopsy should be reserved for cases with atypical findings, such as: age ≥ 60 years, fever, weight loss, bone pain, anemia or leukopenia beyond isolated thrombocytopenia, abnormal smear (schistocytes, immature cells, giant platelets), organomegaly/lymphadenopathy, or lack of response to first‑line therapy. 79
• In a cohort of 127 consecutive children evaluated for suspected ITP, only 5 patients (4 %) had an alternative diagnosis identified on marrow; all five exhibited atypical clinical features. 78

Antiplatelet Antibody Testing

• Platelet‑associated IgG and glycoprotein‑specific antiplatelet antibodies lack sufficient evidence for routine diagnostic use in ITP and are elevated in both immune and non‑immune thrombocytopenia. 79
• Because antibody results do not alter therapeutic decisions, routine testing is not recommended. 79

Management Recommendations

• For pediatric patients with ITP who have no bleeding or only mild skin manifestations (petechiae, ecchymoses), observation alone is the preferred initial approach, irrespective of the absolute platelet count. 79
• Initiation of treatment (e.g., corticosteroids, IVIG) should be based on clinically significant mucosal bleeding (e.g., epistaxis requiring intervention, oral or gastrointestinal bleeding), not solely on platelet numbers. 79

Prognosis

• The majority of children with ITP experience spontaneous remission within 6 months; approximately two‑thirds recover without any therapeutic intervention. 79

Post‑Infectious Immune Thrombocytopenic Purpura (ITP): Evidence‑Based Diagnosis and Management

Pathophysiology

• Acute viral infections (e.g., VZV, EBV, CMV, parvovirus B19, hepatitis A, rubella) are well‑established triggers for secondary ITP, with platelet destruction occurring during or shortly after the infection【80】【81】.

Clinical Presentation

• Post‑infectious ITP typically manifests as isolated thrombocytopenia (platelet count < 100 × 10⁹/L) with a normal complete blood count, appearing 1–4 weeks after resolution of the acute illness【80】.
• Physical examination usually shows only bleeding signs (petechiae, purpura, mucosal bleeding); the presence of splenomegaly, hepatomegaly, or lymphadenopathy suggests alternative diagnoses and excludes primary ITP【80】.

Diagnostic Workup

• Confirm true thrombocytopenia by repeating the platelet count in an anticoagulant tube (citrate or heparin) and reviewing a peripheral smear to rule out pseudothrombocytopenia【80】.
• Verify that thrombocytopenia is isolated through a CBC with differential; any unexplained anemia, leukopenia, or leukocytosis should prompt bone‑marrow evaluation to exclude malignancy or marrow failure【80】.

Mandatory Infectious Testing in Adults

• HIV antibody testing is required for all adults with suspected ITP because HIV‑associated thrombocytopenia can be clinically indistinguishable from primary ITP【80】【81】.
• Hepatitis C virus serology must be obtained in all adults, as chronic HCV can cause secondary ITP that resolves with antiviral therapy【80】【81】.
• Helicobacter pylori testing (urea‑breath test or stool antigen) should be performed, especially in high‑prevalence regions, because eradication normalizes platelet counts in a subset of ITP patients【80】【81】.

Indications for Bone‑Marrow Examination

• Age ≥ 60 years to exclude myelodysplastic syndrome, leukemia, or other malignancies【80】.
• Presence of systemic constitutional symptoms (fever, unexplained weight loss, night sweats, bone pain)【80】.
• Additional cytopenias on CBC beyond isolated thrombocytopenia (e.g., anemia, leukopenia)【80】.
• Organomegaly or lymphadenopathy on physical exam, which points toward secondary causes【80】.

Management Principles

Observation vs. Treatment Decision

• Treatment decisions are guided by bleeding severity rather than platelet count alone; patients with no or only mild skin bleeding should be observed regardless of platelet number【80】.
• In children with platelet counts ≥ 30 × 10⁹/L and no or minor mucocutaneous bleeding, observation is recommended because spontaneous remission occurs in 60–74 % within six months and serious bleeding is rare (intracranial hemorrhage 0.1–0.5 %)【80】.
• Treatment is indicated when clinically significant bleeding occurs, platelet count falls below 10 × 10⁹/L with any bleeding, or an invasive procedure is planned【80】.

First‑Line Therapies (when treatment is required)

• Intravenous immunoglobulin (IVIg) 0.8–1 g/kg as a single dose is preferred in children because it provides rapid platelet rise (24–48 h) with less immunosuppression during acute infection【80】.
• Short‑course corticosteroids (prednisone 1–2 mg/kg/day for 7–14 days) are an alternative but should be used cautiously in the setting of active infection【80】.
• Anti‑D immunoglobulin (50–75 µg/kg) is effective only in Rh(D)‑positive, non‑splenectomized patients and requires Rh(D) typing before use【80】.

Critical Pitfalls to Avoid

• Always have a hematopathologist review the peripheral smear; automated counters may miss pseudothrombocytopenia, giant platelets, or schistocytes, the latter indicating life‑threatening thrombotic microangiopathy【80】.
• Do not omit HIV and hepatitis C testing in adults with suspected ITP, even in low‑risk populations, because these infections can masquerade as primary ITP for years【80】【81】.
• Limit corticosteroid courses in children to short durations (7–14 days) to avoid growth suppression, metabolic effects, and increased infection risk【80】.

Diagnostic Workup and Management of Thrombocytopenia

Peripheral Blood Smear Review

• Manual review of a peripheral blood smear by a hematopathologist is essential because automated counters can miss pseudothrombocytopenia; this step must be completed before any further diagnostic work‑up. 82

Indications for Bone Marrow Examination

• The presence of splenomegaly, hepatomegaly, or lymphadenopathy on physical examination warrants bone‑marrow aspiration and biopsy with flow cytometry and cytogenetics. 82
• Lack of adequate response to first‑line ITP therapies (e.g., intravenous immunoglobulin, corticosteroids, anti‑D) is an indication for bone‑marrow evaluation. 82
• Bone‑marrow assessment is required before performing splenectomy in patients with chronic ITP. 82
• In patients who exhibit typical ITP features (isolated thrombocytopenia, normal physical exam except for bleeding, normal smear morphology, age < 60 years), bone‑marrow examination is not necessary. 82

Tests Not Routinely Ordered

• Measurement of platelet‑associated IgG or glycoprotein‑specific antiplatelet antibodies should not be performed routinely because these assays lack diagnostic specificity and do not influence management decisions. 82

Bleeding‑Risk Stratification by Platelet Count

Management of High‑Titer ANA in Young Adults with Primary ITP

Epidemiology and Risk of Connective‑Tissue Disease

Laboratory Evaluation Recommendations

Clinical Examination Guidance

ITP Treatment Considerations

Evidence‑Based Highlights on Thrombocytopenia

Definition and Laboratory Threshold

• Thrombocytopenia is defined as a platelet count below <150 × 10⁹/L and may result from decreased platelet production, increased platelet destruction, splenic sequestration, or dilution of circulating platelets. 84
• The commonly used laboratory cutoff for diagnosing thrombocytopenia is <150 × 10⁹/L, although exact lower limits can vary slightly among different laboratory reference ranges. 84

Drug‑Induced Mechanisms

• Certain medications can trigger drug‑induced thrombocytopenia, including heparin (which can precipitate heparin‑induced thrombocytopenia), glycoprotein IIb/IIIa inhibitors, quinine, sulfonamides, and many other agents. 85

Thrombotic Paradox in Specific Conditions

Heparin‑Induced Thrombocytopenia (HIT)

• HIT typically manifests with a moderate platelet decline to 30–70 × 10⁹/L occurring 5–10 days after initiation of heparin therapy and is associated with a 30–50 % risk of developing thrombosis. 85

Antiphospholipid Syndrome (APS)

• In APS, thrombocytopenia frequently coexists with a heightened propensity for thrombosis rather than bleeding. 85

Laboratory Evaluation of Thrombocytopenia

1. Core Initial Work‑up

• A complete blood count with differential and manual peripheral‑blood‑smear review by a hematopathologist is the cornerstone of evaluation, allowing exclusion of pseudothrombocytopenia, determination of isolated versus multi‑lineage cytopenias, and identification of morphologic clues that guide further testing. 86
• If EDTA‑dependent platelet clumping is suspected, repeat the platelet count in a citrate or heparin tube; pseudothrombocytopenia occurs in roughly 0.1 % of samples and must be ruled out before any additional work‑up. 86
• Manual smear review is mandatory because automated counters can miss pseudothrombocytopenia, giant platelets, schistocytes, and leukocyte abnormalities that have life‑threatening implications. 86

2. CBC‑Based Criteria

• Isolated thrombocytopenia is defined as a platelet count < 100 × 10⁹/L with normal hemoglobin and white‑blood‑cell count; the presence of any other unexplained cytopenia mandates immediate bone‑marrow examination. 86

3. Peripheral‑Smear Findings and Their Diagnostic Implications

Typical ITP pattern

• Platelets are normal‑sized or only mildly enlarged (not giant). 86
• Red‑cell morphology is normal and lacks schistocytes. 86
• White‑cell morphology is normal, without immature cells or inclusion bodies. 86

Red‑flag findings

• Schistocytes → suggest thrombotic micro‑angiopathy (TTP/HUS/DIC); untreated TTP carries > 90 % mortality, so urgent ADAMTS13 activity, LDH, haptoglobin, and coagulation studies are required. 86
• Giant platelets (approaching red‑cell size) → point to inherited thrombocytopenias such as MYH9‑related disease or Bernard‑Soulier syndrome. 87
• Leukocyte inclusion bodies → characteristic of MYH9‑related disease. 87
• Immature or abnormal white cells → raise suspicion for leukemia or myelodysplastic syndrome. 86

4. Mandatory Infectious‑Disease Screening (All Adults with Suspected ITP)

• HIV antibody testing – HIV‑associated thrombocytopenia is clinically indistinguishable from primary ITP and may precede other HIV manifestations. 86
• Hepatitis C virus serology – chronic HCV can cause secondary ITP that resolves after antiviral therapy. 86
• Helicobacter pylori testing (urea‑breath test or stool antigen) – eradication normalizes platelet counts in a subset of adult ITP patients, especially in high‑prevalence regions. 86

5. Context‑Specific Laboratory Tests

6. Indications for Bone‑Marrow Examination

• Age ≥ 60 years – to exclude myelodysplastic syndrome, leukemia, or other malignancies. 86
• Systemic constitutional symptoms (fever, unexplained weight loss, night sweats, bone pain). 86
• Abnormal CBC parameters beyond isolated thrombocytopenia (unexplained anemia, leukopenia, or leukocytosis). 86
• Atypical peripheral‑smear findings (schistocytes, immature cells, giant platelets, leukocyte inclusion bodies). 86
• Splenomegaly, hepatomegaly, or lymphadenopathy on physical exam – these findings exclude primary ITP. 86
• Minimal or no response to first‑line ITP therapies (IVIg, corticosteroids, anti‑D). 86
• Prior to splenectomy in chronic ITP. 86

Bone‑marrow examination is NOT required in patients with typical ITP features: isolated thrombocytopenia, age < 60 years, normal physical exam except for bleeding, normal smear morphology, and no systemic symptoms. 86

7. Tests That Should Not Be Ordered Routinely

• Platelet‑associated IgG (PaIgG)
• Glycoprotein‑specific antiplatelet antibodies
• Thrombopoietin (TPO) levels
• Reticulated platelet counts
• Bleeding time
• Antiphospholipid antibodies – only if clinical features of antiphospholipid syndrome are present
• Antinuclear antibodies (ANA) – only when systemic lupus erythematosus is suspected

8. Critical Diagnostic Pitfalls

• Never diagnose ITP without hematopathologist review of the peripheral smear; automated counters miss pseudothrombocytopenia, giant platelets, and schistocytes. 86
• Never omit HIV and HCV testing in adults, even in low‑risk populations, because these infections can masquerade as primary ITP and may precede other manifestations by years. 86
• Failure to recognize TTP, HIT, or DIC carries catastrophic mortality risk (untreated TTP > 90 % mortality; HIT thrombosis risk 30‑50 %). Prompt exclusion via smear review, 4T‑score calculation, and coagulation studies is essential. 86
• The presence of splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and mandates investigation for HIV, systemic lupus erythematosus, lymphoproliferative disorders, or chronic liver disease. 86

Guideline Summary for the Evaluation and Management of Thrombocytopenia

1. Pathophysiologic Mechanisms

• Decreased platelet production occurs when bone‑marrow disorders (e.g., myelodysplastic syndromes, leukemias, aplastic anemia, metastatic infiltration) impair megakaryocyte differentiation and platelet release. 90
• Inherited thrombocytopenias (e.g., thrombocytopenia‑absent‑radius syndrome, Wiskott‑Aldrich syndrome, MYH9‑related disease, congenital amegakaryocytic thrombocytopenia) result from genetic defects that disrupt megakaryocyte lineage commitment, maturation, or platelet shedding. 90

2. Diagnostic Evaluation

2.1 Indications for Bone‑Marrow Examination

• Perform bone‑marrow biopsy when patients are ≥ 60 years old, have systemic symptoms (fever, weight loss, bone pain), unexplained anemia or leukopenia, or atypical peripheral‑smear findings (immature cells, giant platelets). 90

2.2 Peripheral‑Smear Review

• Mandatory review by a hematopathologist; the presence of giant platelets suggests inherited thrombocytopenia, whereas schistocytes indicate a thrombotic microangiopathy and trigger urgent ADAMTS13 activity, LDH, haptoglobin, and coagulation testing. 90

2.3 Mandatory Infectious and Microbial Testing in Suspected ITP

• Test all adults with suspected immune thrombocytopenia (ITP) for HIV and hepatitis C, regardless of risk factors, because these infections can masquerade as primary ITP. 90
• Perform Helicobacter pylori testing (urea‑breath test or stool antigen) in adults with suspected ITP; eradication normalizes platelet counts in a subset of patients. 90

2.4 Evaluation for Splenic Sequestration

• Moderate or massive splenomegaly on examination excludes primary ITP and mandates work‑up for chronic liver disease, portal hypertension, lymphoproliferative disorders, or myelofibrosis. 90

2.5 Recognition of Pseudothrombocytopenia

• Automated counters can miss EDTA‑dependent platelet clumping, leading to false low counts in ≈ 0.1 % of samples; hematopathologist review prevents this pitfall. 90

3. Immune‑Mediated Platelet Destruction

3.1 Primary Immune Thrombocytopenia (ITP)

• ITP is an autoimmune disorder characterized by antibody‑mediated destruction of otherwise normal platelets; diagnosis is made only after exclusion of secondary causes. 90

3.2 Secondary Immune Thrombocytopenia

• Associated conditions include HIV, hepatitis C, H. pylori infection, systemic lupus erythematosus, antiphospholipid syndrome, lymphoproliferative disorders, and common variable immune deficiency. 90

3.3 Drug‑Induced Immune Thrombocytopenia

• Can be triggered by heparin, glycoprotein IIb/IIIa inhibitors, quinine, sulfonamides, various antibiotics, and certain chemotherapeutic agents; onset typically 5–14 days after exposure. 91

3.4 Heparin‑Induced Thrombocytopenia (HIT)

• Presents 5–10 days after heparin exposure with moderate thrombocytopenia (30–70 × 10⁹/L) and a high risk of thrombosis (30–50 %).
• The 4T score (thrombocytopenia degree, timing, thrombosis, other causes) guides pre‑test probability; anti‑PF4 antibody testing is mandatory when the score ≥ 4. 91

3.5 Antiphospholipid Syndrome (APS)

• APS may cause thrombocytopenia that is more often accompanied by thrombosis rather than bleeding. 91

4. Non‑Immune Platelet Consumption

• Thrombotic microangiopathies—including thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), and disseminated intravascular coagulation (DIC)—consume platelets via microvascular thrombosis; untreated TTP carries > 90 % mortality. [91][90]

5. Critical Diagnostic Pitfalls

• Failure to recognize TTP, HIT, or DIC leads to catastrophic outcomes (untreated TTP mortality > 90 %; HIT thrombosis risk 30–50 %). Prompt evaluation using peripheral‑smear review, 4T‑score calculation, and coagulation studies is essential. 91
• Missing secondary causes of ITP (HIV, hepatitis C, H. pylori) results in inappropriate management. 90
• Presence of splenomegaly, hepatomegaly, or lymphadenopathy excludes primary ITP and requires investigation for alternative etiologies. 90